These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19166819)

  • 1. NMR structure of the Wnt modulator protein Sclerostin.
    Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD
    Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations.
    Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W
    Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
    van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
    J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
    Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
    J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6.
    Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG
    Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt signaling: a key regulator of bone mass.
    Baron R; Rawadi G; Roman-Roman S
    Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling.
    Shum KT; Chan C; Leung CM; Tanner JA
    Biochem J; 2011 Mar; 434(3):493-501. PubMed ID: 21204783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, purification and functional characterization of Wnt signaling co-receptors LRP5 and LRP6.
    Fleury D; Vayssiere B; Touitou R; Gillard C; Lebhar H; Rawadi G; Mollat P
    Protein Expr Purif; 2010 Mar; 70(1):39-47. PubMed ID: 19716419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cytokines in bone diseases. Wnt signal and excessive bone formation].
    Hosoi T
    Clin Calcium; 2010 Oct; 20(10):1526-31. PubMed ID: 20890035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting sclerostin as potential treatment of osteoporosis.
    Papapoulos SE
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i119-22. PubMed ID: 21339215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
    Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone.
    Salbach-Hirsch J; Samsonov SA; Hintze V; Hofbauer C; Picke AK; Rauner M; Gehrcke JP; Moeller S; Schnabelrauch M; Scharnweber D; Pisabarro MT; Hofbauer LC
    Biomaterials; 2015 Oct; 67():335-45. PubMed ID: 26232882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
    Choi HY; Dieckmann M; Herz J; Niemeier A
    PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin: recent advances and clinical implications.
    Honasoge M; Rao AD; Rao SD
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):437-46. PubMed ID: 25333305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
    Balemans W; Van Hul W
    J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors.
    Choi J; Lee K; Kang M; Lim SK; Tai No K
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1116-1121. PubMed ID: 29486968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
    ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
    J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of an LRP5 cytoplasmic SNP on Wnt signaling and osteoblastic differentiation.
    Guo J; Cooper LF
    Bone; 2007 Jan; 40(1):57-67. PubMed ID: 16956801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin and the unloading of bone.
    Suva LJ
    J Bone Miner Res; 2009 Oct; 24(10):1649-50. PubMed ID: 19757998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.